There have been some encouraging results published regarding the effectiveness of a new drug developed by Eisai called lenvatinib for the treatment of papillary and follicular thyroid cancer which is resistant to radioactive iodine. This drug however, is still a long way from being available for clinical use but Eisai are currently passing it through the regulatory authorities processes.